157 related articles for article (PubMed ID: 31926992)
1. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.
Rezaie E; Amani J; Bidmeshki Pour A; Mahmoodzadeh Hosseini H
Eur J Pharmacol; 2020 Mar; 870():172912. PubMed ID: 31926992
[TBL] [Abstract][Full Text] [Related]
2. A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses.
Naemi AA; Salmanian AH; Noormohammadi Z; Amani J
Eur J Pharmacol; 2023 Sep; 955():175894. PubMed ID: 37429519
[TBL] [Abstract][Full Text] [Related]
3. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
[TBL] [Abstract][Full Text] [Related]
4. Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy.
Shariaty Vaziri Z; Shafiee F; Akbari V
Biotechnol Lett; 2023 Apr; 45(4):537-550. PubMed ID: 36807722
[TBL] [Abstract][Full Text] [Related]
5. Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells.
Lv X; Zhang J; Xu R; Dong Y; Sun A; Shen Y; Wei D
Appl Microbiol Biotechnol; 2016 Jul; 100(14):6403-6413. PubMed ID: 27063011
[TBL] [Abstract][Full Text] [Related]
6. Development of a recombinant hCG-specific single chain immunotoxin cytotoxic to hCG expressing cancer cells.
Nand KN; Gupta JC; Panda AK; Jain SK
Protein Expr Purif; 2015 Feb; 106():10-7. PubMed ID: 25448825
[TBL] [Abstract][Full Text] [Related]
7. Fully human recombinant antibodies against EphA2 from a multi-tumor patient immune library suitable for tumor-targeted therapy.
Yang Y; Nian S; Li L; Wen X; Liu Q; Zhang B; Lan Y; Yuan Q; Ye Y
Bioengineered; 2021 Dec; 12(2):10379-10400. PubMed ID: 34709992
[TBL] [Abstract][Full Text] [Related]
8. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
[TBL] [Abstract][Full Text] [Related]
9. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line.
Bruell D; Stöcker M; Huhn M; Redding N; Küpper M; Schumacher P; Paetz A; Bruns CJ; Haisma HJ; Fischer R; Finnern R; Barth S
Int J Oncol; 2003 Oct; 23(4):1179-86. PubMed ID: 12964002
[TBL] [Abstract][Full Text] [Related]
10. Design and characterization of a recombinant immunotoxin for targeted therapy of breast cancer cells: In vitro and in silico analyses.
Barazesh M; Mohammadi S; Jalili S; Kavousipour S; Faraji SN; Mokarram P; Pirhadi S
Life Sci; 2021 Jan; 265():118866. PubMed ID: 33301810
[TBL] [Abstract][Full Text] [Related]
11. Construction, expression, and characterization of a recombinant immunotoxin targeting EpCAM.
Lv M; Qiu F; Li T; Sun Y; Zhang C; Zhu P; Qi X; Wan J; Yang K; Zhang K
Mediators Inflamm; 2015; 2015():460264. PubMed ID: 25960617
[TBL] [Abstract][Full Text] [Related]
12. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.
Dunn RD; Weston KM; Longhurst TJ; Lilley GG; Rivett DE; Hudson PJ; Raison RL
Immunotechnology; 1996 Sep; 2(3):229-40. PubMed ID: 9373315
[TBL] [Abstract][Full Text] [Related]
13. Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum.
Jiao P; Zhang J; Dong Y; Wei D; Ren Y
Appl Microbiol Biotechnol; 2018 Nov; 102(22):9585-9594. PubMed ID: 30141083
[TBL] [Abstract][Full Text] [Related]
14. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.
Niesen J; Brehm H; Stein C; Berges N; Pardo A; Fischer R; Ten Haaf A; Gattenlöhner S; Tur MK; Barth S
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1049-61. PubMed ID: 25433506
[TBL] [Abstract][Full Text] [Related]
15. A new recombinant immunotoxin hscFv-ETA' demonstrates specific cytotoxicity against chronic myeloid leukemia cells in vitro.
Zhu X; Tao K; Li Y; Li S; Zhang L; Wang D; Zhong L; Feng W
Immunol Lett; 2013; 154(1-2):18-24. PubMed ID: 23954809
[TBL] [Abstract][Full Text] [Related]
16. Recombinant anti-human epidermal growth factor receptor type 2 single-chain variable fragment-alpha-luffin fusion protein as a putative immunotoxin against human epidermal growth factor receptor type 2-positive breast cancer cells: an experimental research.
Damough S; Bayat E; Oghabi Bakhshaiesh T; Barkhordari F; Esmaeili R; Nematollahi L; Talebkhan Y
Ann Med Surg (Lond); 2023 Sep; 85(9):4348-4354. PubMed ID: 37663730
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
18. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
19. Production and introduction of a novel immunotoxin based on engineered RNase A for inducing death to Her1-positive cell lines.
Forouharmehr A; Nassiri M; Ghovvati Roudsari S; Javadmanesh A
J Cell Physiol; 2020 May; 235(5):4679-4687. PubMed ID: 31663127
[TBL] [Abstract][Full Text] [Related]
20. Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scFvs: involvement of bioinformatics-based design of novel epitopes.
Zarei N; Fazeli M; Mohammadi M; Nejatollahi F
Breast Cancer Res Treat; 2018 Jun; 169(3):427-436. PubMed ID: 29411237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]